bictegravir/emtricitabine/tenofovir vs carbamazepine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and carbamazepine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Anticonvulsants: carbamazepine Drug-drug interaction study was conducted with either BIKTARVY or its components as individual agents.
Biktarvy
Tegretol
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Carbamazepine is a medicine used to control seizures and treat nerve pain. It works by reducing abnormal electrical activity in the brain and calming nerve signals.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
Carbamazepine is used to treat certain types of seizures, including partial seizures and generalized tonic-clonic seizures. It can also treat mixed seizure patterns. Carbamazepine also treats the pain from trigeminal neuralgia, a nerve disorder that causes intense facial pain. It is also sometimes used for glossopharyngeal neuralgia.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Carbamazepine is an anticonvulsant. It works by reducing the spread of seizure activity in the brain. It also stabilizes nerve impulses to reduce pain.
- • Diarrhea
- • Nausea
- • Headache
- • Dizziness
- • Drowsiness
- • Unsteadiness
- • Nausea
- • Vomiting
No adverse event reports.
- Seizure 3,609
- Drug Interaction 3,369
- Fall 3,044
- Dizziness 2,862
- Pyrexia 2,689
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
Carbamazepine can cause severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal. If you are of Asian descent, you may need a blood test before starting this medicine. Carbamazepine can also cause serious blood problems like aplastic anemia and agranulocytosis. Contact your doctor right away if you develop a fever, sore throat, rash, or unusual bleeding or bruising.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Carbamazepine may harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if carbamazepine passes into breast milk, so talk to your doctor about breastfeeding.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
Compare carbamazepine with
How to Read This bictegravir/emtricitabine/tenofovir vs carbamazepine Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while carbamazepine sits within the Anticonvulsant class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while carbamazepine has 15,573. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to carbamazepine can speed up the body's breakdown of the hiv medication, which may make the treatment less effective.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bictegravir/emtricitabine/tenofovir or carbamazepine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.